Table 3 |
||||
|
Clinical and parasitological responses to treatment with artemether-lumefantrine by body weight group |
||||
| Body weight group |
||||
| Characteristic |
BWG1 5-<10 kg |
BWG2 10-<15 kg |
BWG3 15-<25 kg |
Total 5-<25 kg |
|
|
||||
| Cure rates ITT %(n/M)1 (uncorrected) |
N = 50 |
N = 37 |
N = 16 |
N = 103 |
| Day 7 |
98.0% (49/50) |
97.3% (36/37) |
100.0% (16/16) |
98.1% (101/103) |
| Day 14 |
96.0% (48/50) |
94.6% (35/37) |
93.8% (15/16) |
95.1% (98/103) |
| Day 28 |
92.0% (46/50) |
89.2% (33/37) |
93.8% (15/16) |
91.3% (94/103) |
| 95% CI |
(80.8–97.8) |
(74.6–97.0) |
(69.8–99.8) |
(84.1–95.9) |
| Day 28 (PCR corrected) |
96.0% (48/50) |
94.6% (35/37) |
93.8% (15/16) |
95.1% (98/103) |
| 95% CI |
(86.3–99.5) |
(81.8–99.3) |
(69.8–99.8) |
(89.0–98.4) |
| Cure rate PP %(n/M)1 (uncorrected) |
N = 45 |
N = 34 |
N = 14 |
N = 93 |
| Day 7 |
100% (45/45) |
100% (34/34) |
100% (14/14) |
100% (93/93) |
| Day 14 |
100% (45/45) |
100% (34/34) |
100% (13/13) |
100% (92/92) |
| Day 28 |
95.6% (43/45) |
94.1% (32/34) |
100% (13/13) |
95.7% (88/92) |
| 95% CI |
(84.9–99.5) |
(80.3 – 99.3) |
(-) |
(89.2 – 98.8) |
| PCT (h) ITT |
N = 50 |
N = 37 |
N = 16 |
N = 103 |
| Mean ± SE |
24.8 ± 1.3 |
26.2 ± 2.31 |
21.2 ± 4.33 |
24.9 ± 1.28 |
| Range |
5.3 – 47.8 |
7.7 – 59.9 |
7.2 – 71.1 |
5.3–71.1 |
| Median |
23.8 |
23.8 |
23.0 |
23.8 |
| 95%CI2 |
(23.7–23.9) |
(23.1–35.3) |
(7.9–23.8) |
(23.7–23.8) |
| FCT (h) ITT) |
N = 50 |
N = 37 |
N = 16 |
N = 103 |
| Mean ± SE |
24.5 ± 3.81 |
17.6 ± 2.04 |
44.2 ± 19.98 |
26.1 ± 4.14 |
| Range |
3.5 – 163.8 |
4.1 – 47.5 |
7.2–308.7 |
3.5–308.7 |
| Median |
23.4 |
8.2 |
15.4 |
22.4 |
| (95% CI)2 |
(7.8–23.8) |
(7.8–23.4) |
(7.8–34.6) |
(7.9–23.5) |
|
|
||||
|
1In some instances N is different from M as M = number of patients who had the measurement at given time point 2The CI is provided for the median |
||||
|
Falade et al. Malaria Journal 2008 7:246 doi:10.1186/1475-2875-7-246 |
||||
